Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Single-dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BI 3000202 in Adults

NCT07486102 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07486102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07486102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Single-dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BI 3000202 in Adults
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
May 1, 2026
Completion date
February 27, 2027
Enrollment
44 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, hepatic impairment